Structure Therapeutics Inc. 8-K

What Happened

• On May 7, 2026, Structure Therapeutics Inc. announced an amendment and restatement of its August 6, 2025 sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The Amended and Restated Sales Agreement removes the prior aggregate offering cap for the Company’s American Depositary Shares (ADSs; each ADS represents three ordinary shares).
• The company also filed a prospectus supplement to its Form S-3ASR (File No. 333-289326) on May 7, 2026, increasing the ATM capacity by $150,000,000 for an aggregate offering price of up to $400,000,000. Separately, Structure issued a press release on May 7, 2026 providing a corporate update and reporting its financial results for the quarter ended March 31, 2026 (press release furnished as Exhibit 99.1).

Key Details

• Sales agents: Leerink Partners LLC and Cantor Fitzgerald & Co. (unchanged).
• Prospectus supplement increases ATM availability by $150 million, for an aggregate offering price up to $400 million.
• Prior to the supplement, the company sold 3,040,000 ADSs under the Sales Agreement for gross proceeds of approximately $58,520,000.
• Legal opinion on ATM share validity from Travers Thorp Alberga is included as Exhibit 5.1; consent is included in that exhibit.

Why It Matters

• The amendment and prospectus supplement give Structure Therapeutics greater flexibility to raise capital through at-the-market (ATM) sales of ADSs, potentially up to $400 million in aggregate, which can be used for operations, R&D, or other corporate needs.
• Retail investors should review the May 7, 2026 press release (Exhibit 99.1) for the company’s reported first-quarter financial results and corporate update; the press release is furnished with the 8-K but is not deemed “filed” for certain regulatory liability purposes.